Lymphoma Treatment Concepts for Internal Medicine Bo... | MDster You are offline Back online! [ MDster home ](/ "MDster home") Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Medical Education ](https://mdster.com/blog?category=medical-education) 4. Lymphoma Treatment Concepts: Chemoimmunotherapy, CNS, and RT [ Medical Education ](https://mdster.com/blog?category=medical-education) Lymphoma Treatment Concepts: Chemoimmunotherapy, CNS, and RT ============================================================== A practical framework for selecting systemic therapy, considering CNS prophylaxis, and using radiation selectively [ MDster Editorial Team ](https://mdster.com/about) · Aug 25, 2026 · 5 min read · 41 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Internal Medicine ](https://mdster.com/blog?tag=internal-medicine) [ Hematologic Malignancies ](https://mdster.com/blog?tag=hematologic-malignancies) [ Lymphoma ](https://mdster.com/blog?tag=lymphoma) [ Chemoimmunotherapy ](https://mdster.com/blog?tag=chemoimmunotherapy) [ Radiation Oncology ](https://mdster.com/blog?tag=radiation-oncology) ![Lymphoma Treatment Concepts: Chemoimmunotherapy, CNS, and RT](https://mdster.com/storage/blog/images/lymphoma-treatment-concepts-chemoimmunotherapy-cns-and-rt.jpg) Share this article Share this post On this page 1. [ Start With Biology, Not the Regimen Name ](#start-with-biology-not-the-regimen-name) 2. [ Recognize the major treatment patterns ](#recognize-the-major-treatment-patterns) 3. [ CNS Prophylaxis: Risk-Stratify, Then Admit the Uncertainty ](#cns-prophylaxis-risk-stratify-then-admit-the-uncertainty) 4. [ Radiation Therapy: Use a Scalpel, Not a Floodlight ](#radiation-therapy-use-a-scalpel-not-a-floodlight) 5. [ Clinical Correlations for the Internist ](#clinical-correlations-for-the-internist) 6. [ Key Takeaways ](#key-takeaways) 7. [ Conclusion ](#conclusion) 8. [ Frequently Asked Questions ](#blog-faqs) 9. [ References ](#references-heading) On this page 1. [ Start With Biology, Not the Regimen Name ](#start-with-biology-not-the-regimen-name) 2. [ Recognize the major treatment patterns ](#recognize-the-major-treatment-patterns) 3. [ CNS Prophylaxis: Risk-Stratify, Then Admit the Uncertainty ](#cns-prophylaxis-risk-stratify-then-admit-the-uncertainty) 4. [ Radiation Therapy: Use a Scalpel, Not a Floodlight ](#radiation-therapy-use-a-scalpel-not-a-floodlight) 5. [ Clinical Correlations for the Internist ](#clinical-correlations-for-the-internist) 6. [ Key Takeaways ](#key-takeaways) 7. [ Conclusion ](#conclusion) 8. [ Frequently Asked Questions ](#blog-faqs) 9. [ References ](#references-heading) A patient with bulky adenopathy can receive curative chemotherapy, observation, targeted immunotherapy, or radiation—and each choice may be correct for a different lymphoma. The dangerous mistake is treating “lymphoma” as one disease. Always anchor treatment to histology, stage, molecular features, treatment intent, and patient fitness. Start With Biology, Not the Regimen Name ---------------------------------------- Chemoimmunotherapy combines cytotoxic drugs with an antibody, antibody-drug conjugate, or checkpoint inhibitor directed at lymphoma biology. It improves tumor killing without relying solely on escalating chemotherapy intensity. ### Recognize the major treatment patterns As of August 2026, nivolumab plus AVD (N-AVD) is an FDA-approved and preferred U.S. frontline option for stage III–IV classic Hodgkin lymphoma (cHL). Brentuximab vedotin plus AVD (BV-AVD) remains an alternative when checkpoint inhibition is unsuitable, while ABVD remains relevant in selected settings. Early-stage cHL commonly receives ABVD-based chemotherapy with or without involved-site radiation therapy (ISRT). [\[1\]](#cite-1 "Reference [1]") Disease patternCore treatment conceptCommon trapAdvanced cHLN-AVD; BV-AVD in selected patientsAssuming bleomycin remains mandatoryDLBCLPola-R-CHP for many patients with IPI 2–5; R-CHOP remains standardTreating every CD20-positive lymphoma identicallyIndolent B-cell NHLObserve asymptomatic disease; use anti-CD20-based therapy when indicatedTreating advanced stage without a clinical indicationCD30-positive PTCLBrentuximab vedotin plus CHP in appropriate subtypesIgnoring antigen expression and histology In DLBCL, pola-R-CHP improves progression-free survival compared with R-CHOP in intermediate- or high-risk disease, although an overall-survival advantage has not been established. Indolent lymphomas require a different mindset: advanced radiographic stage alone does not mandate treatment. [\[2\]](#cite-2 "Reference [2]") Before anti-CD20 therapy, check HBsAg, anti-HBc, and anti-HBs and arrange antiviral prophylaxis when indicated. Also assess anthracycline cardiac risk, fertility goals, infection risk, and tumor lysis syndrome risk. Never let the regimen name distract you from preventing avoidable toxicity. [\[3\]](#cite-3 "Reference [3]") CNS Prophylaxis: Risk-Stratify, Then Admit the Uncertainty ---------------------------------------------------------- Routine CNS prophylaxis is not indicated for cHL or most indolent lymphomas. It is built into treatment protocols for Burkitt and lymphoblastic lymphoma, but its role in DLBCL remains controversial. Calculate the **CNS-IPI**, which includes age over 60, ECOG performance status of at least 2, elevated LDH, stage III–IV disease, more than one extranodal site, and kidney or adrenal involvement. Scores of 4–6 identify a high-risk group, but the score should trigger specialist assessment—not automatic methotrexate. Pay particular attention to testicular and kidney/adrenal involvement. These sites may prompt prophylaxis discussions even when the overall score is not striking. New neurologic symptoms require diagnostic evaluation with brain MRI and appropriate CSF studies; prophylaxis is not treatment for established CNS disease. Intrathecal methotrexate mainly exposes the CSF and does not reliably protect the brain parenchyma. High-dose IV methotrexate penetrates systemically but carries renal, mucosal, and scheduling toxicity. Contemporary retrospective data and meta-analyses have not demonstrated a clear reduction in CNS relapse for most high-risk DLBCL patients. Avoid delaying curative systemic therapy while forcing an unproven prophylactic strategy. [\[2\]](#cite-2 "Reference [2]") Radiation Therapy: Use a Scalpel, Not a Floodlight -------------------------------------------------- Modern lymphoma radiation uses **ISRT**, targeting initially involved anatomy rather than historical extended fields. Preserve the baseline PET/CT because radiation planning depends on where disease was located before chemotherapy changed the anatomy. [\[4\]](#cite-4 "Reference [4]") Radiation remains valuable for: - Early-stage cHL as part of combined-modality therapy. - Localized follicular or marginal-zone lymphoma, sometimes with curative intent. - Selected limited-stage DLBCL. - Bulky or persistently PET-positive sites after systemic therapy. - Palliation of painful, obstructive, or organ-threatening disease. Do not irradiate a residual mass solely because it remains visible. Integrate PET avidity, original disease distribution, histology, biopsy feasibility, and late toxicity risks involving the heart, lungs, breasts, and thyroid. > **Clinical Pearl:** A PET-negative residual mass after appropriate lymphoma therapy is usually not an automatic indication for radiation. Metabolic response matters more than persistent size. Clinical Correlations for the Internist --------------------------------------- Monitor for febrile neutropenia, tumor lysis syndrome, anthracycline cardiotoxicity, bleomycin lung injury, neuropathy, HBV reactivation, and immune-related adverse events. Checkpoint-associated diarrhea, hepatitis, pneumonitis, or endocrinopathy should not be dismissed as routine chemotherapy toxicity. Interim PET is central to response-adapted cHL strategies. In DLBCL, however, do not switch curative therapy solely because an interim PET remains positive outside a validated protocol; false-positive inflammatory uptake is common. Key Takeaways ------------- - Treat the histologic subtype, not the word “lymphoma.” - Match immunotherapy to its target: CD20, CD30, or PD-1 biology. - Use CNS-IPI and high-risk extranodal sites to guide—not dictate—prophylaxis. - Recognize that CNS prophylaxis evidence in DLBCL remains weak. - Use modern ISRT selectively and never equate residual mass with active disease. Conclusion ---------- Lymphoma treatment is a risk-adapted sequence of decisions, not a memorized regimen list. Get the pathology right, protect curative systemic therapy, and reserve CNS prophylaxis and radiation for patients whose biology and anatomy justify them. Frequently Asked Questions ---------------------------- ### Is R-CHOP still a standard first-line treatment for DLBCL in 2026? Yes. R-CHOP remains standard, while pola-R-CHP is a frontline option for many patients with IPI scores of 2–5. Selection depends on pathology, risk, comorbidities, toxicity, and access. ### Which DLBCL patients should be considered for CNS prophylaxis? Consider specialist assessment for patients with a high CNS-IPI or high-risk sites such as the testes, kidneys, or adrenal glands. Prophylaxis is individualized because evidence of benefit remains limited. ### Does intrathecal methotrexate prevent brain parenchymal lymphoma relapse? Not reliably. Intrathecal therapy primarily treats the CSF compartment and provides limited brain parenchymal exposure. ### When is radiation therapy most useful in lymphoma? Radiation is useful in early-stage cHL, localized indolent lymphoma, selected limited-stage DLBCL, persistently PET-positive sites, and palliation of symptomatic disease. References (7) ------------------ 1. 1. [ FDA approval of nivolumab plus AVD for previously untreated stage III–IV cHL, March 20, 2026 ](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-chemotherapy-previously-untreated-hodgkin-lymphoma) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ NCI PDQ: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment ](https://www.cancer.gov/types/lymphoma/hp/aggressive-b-cell-lymphoma-treatment-pdq) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ ascopubs.org/doi/pdfdirect/10.1200/JCO.20.01757 ](https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.01757) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ Wirth A et al. Involved Site Radiation Therapy in Adult Lymphomas. Int J Radiat Oncol Biol Phys. 2020 ](https://pubmed.ncbi.nlm.nih.gov/32272184/) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ NCI PDQ: Hodgkin Lymphoma Treatment—Health Professional Version ](https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq) 6. 6. [ Wilson MR et al. CNS prophylaxis in large B-cell lymphoma. Br J Haematol. 2024 ](https://pubmed.ncbi.nlm.nih.gov/39128894/) 7. 7. [ ASCO: Hepatitis B Virus Screening and Management Before Cancer Therapy ](https://ascopubs.org/doi/10.1200/JCO.20.01757) Keep going Turn reading into Internal Medicine performance ------------------------------------------------- - System‑based, exam‑style questions + explanations - Smarter review to reinforce weak topics - Build confidence with measurable progress [ Start practicing ](https://mdster.com/user/dashboard) [ Explore Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features\*. No commitment. Cancel anytime. \*AI SOE Examiner is limited to 10 cases monthly for Advanced & Bundle subscribers. Explore topics: [ # Internal Medicine ](https://mdster.com/blog?tag=internal-medicine) [ # Hematologic Malignancies ](https://mdster.com/blog?tag=hematologic-malignancies) [ # Lymphoma ](https://mdster.com/blog?tag=lymphoma) [ # Chemoimmunotherapy ](https://mdster.com/blog?tag=chemoimmunotherapy) [ # Radiation Oncology ](https://mdster.com/blog?tag=radiation-oncology) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Medical Education ------------------------- [ See all ](https://mdster.com/blog?category=medical-education) [### Pediatric Coma Evaluation in the ICU: A High-Yield Approach 5 min read Aug 24, 2026 ](https://mdster.com/blog/pediatric-coma-evaluation-in-the-icu-a-high-yield-approach) [### Arterial Access Anatomy: Radial, Femoral, and Pedal Sites 5 min read Aug 23, 2026 ](https://mdster.com/blog/arterial-access-anatomy-radial-femoral-and-pedal-sites) [### GI Bleeding Risk Stratification and Disposition in the ED 5 min read Aug 22, 2026 ](https://mdster.com/blog/gi-bleeding-risk-stratification-and-disposition-in-the-ed) Related Posts ------------- [ ![Pediatric Coma Evaluation in the ICU: A High-Yield Approach](https://mdster.com/storage/blog/images/pediatric-coma-evaluation-in-the-icu-a-high-yield-approach.jpg) Medical Education ### Pediatric Coma Evaluation in the ICU: A High-Yield Approach Evaluate pediatric coma systematically using empiric treatment thresholds, a structured differential, targeted laboratory testing, EEG, lumbar puncture, CT, and MRI. 5 min read 0 comments ](https://mdster.com/blog/pediatric-coma-evaluation-in-the-icu-a-high-yield-approach) [ ![Arterial Access Anatomy: Radial, Femoral, and Pedal Sites](https://mdster.com/storage/blog/images/arterial-access-anatomy-radial-femoral-and-pedal-sites.jpg) Medical Education ### Arterial Access Anatomy: Radial, Femoral, and Pedal Sites Learn the anatomy that makes arterial lines safe: assess radial collateral flow, avoid high femoral punctures, and select pedal arteries wisely. 5 min read 0 comments ](https://mdster.com/blog/arterial-access-anatomy-radial-femoral-and-pedal-sites) [ ![GI Bleeding Risk Stratification and Disposition in the ED](https://mdster.com/storage/blog/images/gi-bleeding-risk-stratification-and-disposition-in-the-ed.jpg) Medical Education ### GI Bleeding Risk Stratification and Disposition in the ED Identify low-risk GI bleeds for discharge, recognize admission triggers, time endoscopy appropriately, and use observation and repeat hemoglobin wisely. 5 min read 0 comments ](https://mdster.com/blog/gi-bleeding-risk-stratification-and-disposition-in-the-ed) [ ![Ventilator-Associated Pneumonia: A Case-Based Management Guide](https://mdster.com/storage/blog/images/ventilator-associated-pneumonia-a-case-based-management-guide.jpg) Case Discussion ### Ventilator-Associated Pneumonia: A Case-Based Management Guide A case-based approach to diagnosing ventilator-associated pneumonia, selecting empiric antibiotics, interpreting cultures, and preventing unnecessary treatment. 6 min read 0 comments ](https://mdster.com/blog/ventilator-associated-pneumonia-a-case-based-management-guide) [ ![Actuarial Violence Risk Assessment Tools in Forensic Psychiatry](https://mdster.com/storage/blog/images/actuarial-violence-risk-assessment-tools-in-forensic-psychiatry.jpg) Medical Education ### Actuarial Violence Risk Assessment Tools in Forensic Psychiatry Learn how actuarial violence risk tools work, what their scores mean, and how to apply them ethically without overstating individual predictive certainty. 5 min read 0 comments ](https://mdster.com/blog/actuarial-violence-risk-assessment-tools-in-forensic-psychiatry) [ ![When to Start an Infertility Workup: Age, Risks, and Loss](https://mdster.com/storage/blog/images/when-to-start-an-infertility-workup-age-risks-and-loss.jpg) Medical Education ### When to Start an Infertility Workup: Age, Risks, and Loss Learn the age-based infertility evaluation thresholds, which risk factors bypass the clock, and how prior pregnancy loss or complications change timing. 5 min read 0 comments ](https://mdster.com/blog/when-to-start-an-infertility-workup-age-risks-and-loss) [ MDster home ](/ "MDster home") Master your medical exams with evidence-based learning. [ Download on the App Store ](https://apps.apple.com/app/id6759168258) [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://apps.apple.com/app/id6759168258) [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept